Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.

W Arcese, , A Picardi, S Santarone, G De Angelis, R Cerretti, L Cudillo, E Pennese, P Bavaro, P Olioso, T Dentamaro, L Cupelli, A Chierichini, A Ferrari, A Mengarelli, M C Tirindelli, M Testi, F Di Piazza, P Di Bartolomeo, Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update. Bone Marrow Transplantation. ,vol. 50, ,(2015) , 10.1038/BMT.2015.91

Ryotaro Nakamura, Joycelynne M. Palmer, Margaret R. O’Donnell, Tracey Stiller, Sandra H. Thomas, Joseph Chao, Joseph Alvarnas, Pablo M. Parker, Vinod Pullarkat, Rodrigo Maegawa, Anthony S. Stein, David S. Snyder, Ravi Bhatia, Karen Chang, Shirong Wang, Ji-Lian Cai, David Senitzer, Stephen J. Forman, Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis Leukemia Research. ,vol. 36, pp. 1152- 1156 ,(2012) , 10.1016/J.LEUKRES.2012.04.022

J Sanz, , J C H Boluda, C Martín, M González, C Ferrá, D Serrano, C D de Heredia, C Barrenetxea, A M Martinez, C Solano, M A Sanz, G F Sanz, Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplantation. ,vol. 47, pp. 1287- 1293 ,(2012) , 10.1038/BMT.2012.13

Boglarka Gyurkocza, Brenda M. Sandmaier, Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. ,vol. 124, pp. 344- 353 ,(2014) , 10.1182/BLOOD-2014-02-514778

Birgit Cremer, Brenda M. Sandmaier, Wolfgang Bethge, Thoralf Lange, Valentin Goede, Udo Holtick, Michael Hallek, Kai Hübel, Reduced-intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective. Onkologie. ,vol. 34, pp. 710- 715 ,(2011) , 10.1159/000334542

Manuel Hidalgo, Eric K Rowinsky, The rapamycin-sensitive signal transduction pathway as a target for cancer therapy Oncogene. ,vol. 19, pp. 6680- 6686 ,(2000) , 10.1038/SJ.ONC.1204091

E. Carreras, A. Grañena, C. Rozman, Hepatic veno-occlusive disease after bone marrow transplant Blood Reviews. ,vol. 7, pp. 43- 51 ,(1993) , 10.1016/0268-960X(93)90023-W

Zaid Al-Kadhimi, Zartash Gul, Roberto Rodriguez, Wei Chen, Daryn Smith, Alice Mitchell, Muneer Abidi, Lois Ayash, Abhinav Deol, Lawrence Lum, Stephen Forman, Voravit Ratanatharathorn, Joseph Uberti, Anti-Thymocyte Globulin (Thymoglobulin), Tacrolimus, and Sirolimus as Acute Graft-versus-Host Disease Prophylaxis for Unrelated Hematopoietic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. ,vol. 18, pp. 1734- 1744 ,(2012) , 10.1016/J.BBMT.2012.06.004

Corey Cutler, Kristen Stevenson, Haesook T. Kim, Paul Richardson, Vincent T. Ho, Erica Linden, Carolyn Revta, Ruth Ebert, Diane Warren, Sung Choi, John Koreth, Philippe Armand, Edwin Alyea, Shelly Carter, Mary Horowitz, Joseph H. Antin, Robert Soiffer, Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation Blood. ,vol. 112, pp. 4425- 4431 ,(2008) , 10.1182/BLOOD-2008-07-169342

Roberto Rodriguez, Ryotaro Nakamura, Joycelynne M. Palmer, Pablo Parker, Sepideh Shayani, Auyaporn Nademanee, David Snyder, Vinod Pullarkat, Neil Kogut, Joseph Rosenthal, Eileen Smith, Chatchada Karanes, Margaret O'Donnell, Amrita Y. Krishnan, David Senitzer, Stephen J. Forman, A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens Blood. ,vol. 115, pp. 1098- 1105 ,(2010) , 10.1182/BLOOD-2009-03-207563